Last month, the FTC voted unanimously to examine rising list prices of insulin, but also to probe possible anti-competitive practices by PBMs. Proof of the establishment of anti-competitive practices - such as rebate walls - would likely lead to legal action being taken against PBMs.
Subscribe to:
Post Comments (Atom)
< + > Why AI-Enabled Throughput Tools Fail Early and What Signal Infrastructure Fixes
The following is a guest article by Steve Biko Onyambu, MD, Critical Care Physician at Abbott Northwestern Hospital Hospital leaders invest...
No comments:
Post a Comment